Genmab AS has the GF Score of 93, which implies that the company
might have
Highest outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Genmab AS
might have
Highest outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Genmab AS (OTCPK:GNMSF) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Genmab AS GF Score Related Terms
GNMSF vs VRTX, REGN, ALNY: GF Score Comparison
For the Biotechnology subindustry, Genmab AS's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's GF Score distribution charts can be found below:
* The bar in red indicates where Genmab AS's GF Score falls into.
Genmab AS (GNMSF) has a GF Score of 93 as of Jul. 05, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Genmab AS and its competitors. This is near median its historical median of 87.00. Over the past decade, Genmab AS's GF Score has ranged from 58.00 to 99.00.
Is Genmab AS's GF Score too high?
Genmab AS's current GF Score of 93 is near median its 10-year median of 87.00. Over the past 10 years, this metric has ranged from a low of 58.00 to a high of 99.00. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's GF Score compare to VRTX and REGN?
Genmab AS's GF Score of 93 can be compared against companies in the Biotechnology industry. Historically, Genmab AS's own GF Score has ranged from 58.00 to 99.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Genmab AS and its competitors. Genmab AS's current GF Score is 93, which is near median its own 10-year median of 87.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $337.53, compared to a current price of $275.00 — trading 18.5% below its estimated fair value. The current GF Score is 93, which is near median its 10-year median of 87.00. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Genmab AS (GNMSF), the current GF Score is 93 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (GNMSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of $275.00 is trading 18.5% below its estimated GF Value™ of $337.53.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for GNMSF:
GF Score: 93 (near median its 10-year median of 87.00)
GF Value™: $337.53 vs. price of $275.00 (18.5% below fair value)
No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score
Get the complete analysis for GNMSF
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNMSF has been successfully added to your 